We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FENOFIB Accelagen Pty Ltd
Product name
FENOFIB
Sponsor
Accepted date
Sep-2025
Active ingredients
fenofibrate
Proposed indication
Fenofib (fenofibrate) is proposed to help manage conditions that present with abnormal levels of blood lipids including:
High cholesterol: Fenofib may lower cholesterol levels, particularly when diet and lifestyle changes alone are not enough.
Dyslipidaemia: including types II, III, IV, and V.
Type 2 Diabetes: For people with type 2 diabetes, Fenofib may help manage blood fat problems that are common with this condition.
Diabetic retinopathy: Fenofib may slow the progression of diabetic retinopathy (damage to the small blood vessels in the eyes) in people with type 2 diabetes who already have this complication. However, it is not intended to substitute for good control of blood pressure, blood sugar, and blood fats.
Reducing amputation risk: In patients with type 2 diabetes, Fenofib may reduce the risk of diabetes-related non-traumatic amputations.
High cholesterol: Fenofib may lower cholesterol levels, particularly when diet and lifestyle changes alone are not enough.
Dyslipidaemia: including types II, III, IV, and V.
Type 2 Diabetes: For people with type 2 diabetes, Fenofib may help manage blood fat problems that are common with this condition.
Diabetic retinopathy: Fenofib may slow the progression of diabetic retinopathy (damage to the small blood vessels in the eyes) in people with type 2 diabetes who already have this complication. However, it is not intended to substitute for good control of blood pressure, blood sugar, and blood fats.
Reducing amputation risk: In patients with type 2 diabetes, Fenofib may reduce the risk of diabetes-related non-traumatic amputations.
Application type
C (new indication)
Publication date
Sep-2025